Bmeta
Digital Diagnostics
“Our technology is the endgame, it's the diagnostics solution that will change everything” - Dr. Greg Hummer 2021
In partnership with IdentifySensors Biologics, Bmeta is setting the stage for the next generation, cutting edge, telemedicine platform. Through blockchain technology & ground breaking molecular diagnostics science, together they are shaping the future of medicine.
Welcome to the new face of telemedicine, Bmeta Diagnostics.
With the help of some of the smartest minds on this planet, we will ensure the future ability to have secure, private yet extremely personal medical consultations with your primary care physician, right from home.
While utilizing the power of the Check4 platform and blockchain technology, Bmeta is building premium services that will offer same day diagnostics coupled with same day treatment.
In major cities we will have medicine depositories that will work closely with UPS Sonic Air & Amazon to be able to offer delivery in just hours. This extremely disruptive technology paired with the power of Web 3 will make our world a healthier place.
Tune in to the Bman Wilder Show for regular interviews with Dr Greg Hummer and technology updates as we shuffle this technology through the FDA process.
Check4® by IdentifySensors Biologics® is a next-generation digital diagnostic platform intended to detect multiple pathogens within 5 minutes at the gene level.
The platform eliminates the need for enzymatic amplification and reagents. Graphene sensor technology has moved diagnostics beyond chemical testing into a rapid digital platform as accurate as a PCR test but significantly more sensitive and cost effective.
Printed graphene sensors isolate targeted viruses and bacteria from saliva and other bodily fluids within a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for over-the-counter and point-of-care use.
With a target price at a fraction of current molecular tests, Check4® is intended to disrupt the PCR market for many infections. Future plans for the platform include rapidly detecting biomarkers and T-cell immunity, in conjunction with direct diagnosis to help clinicians predict infection severity and vaccine effectiveness among individual patients.
